Cape Town-based medical technology startup Impulse Biomedical has secured a new round of investment from E Squared Investments and ANZA Capital to accelerate the commercialisation and international deployment of its emergency care solutions. The precise amount of capital raised has not been disclosed, but the funding is a significant step forward in scaling the company’s innovative healthcare technologies globally.
Founded by biomedical engineering graduates Giancarlo Beukes and Gokul Nair, the company is known for pioneering life-saving devices aimed at increasing accessibility and affordability in emergency care, particularly within underserved populations. Its two flagship products, the Easy Squeezy and the ZiBiPen, have garnered industry attention for addressing long-standing gaps in respiratory and anaphylactic treatment, respectively.
The Easy Squeezy is an affordable, user-friendly asthma inhaler designed to empower patients—particularly those in low-income or resource-constrained settings—to better manage chronic respiratory conditions. The device enhances medication delivery while simplifying the inhalation process, a key challenge among children and the elderly.
The ZiBiPen, meanwhile, is touted as the world’s first reloadable epinephrine auto-injector. The innovation presents a sustainable and economically viable alternative to traditional auto-injectors, which are typically single-use and cost-prohibitive in many regions. The ZiBiPen’s reloadable cartridge system significantly reduces waste and recurring costs, making it a potentially transformative solution in allergy management and anaphylaxis treatment.
This new funding round follows earlier backing from Futuregrowth Asset Management, a South African investment firm that initially invested in the startup in 2021. According to Impulse Biomedical, the current investment will enable the company to navigate the regulatory complexities of multiple markets, strengthen its manufacturing capacity, and lay the groundwork for a forthcoming Series A capital raise.
In a statement, co-founder Giancarlo Beukes described the new partnership as “a pivotal step” in the company’s strategic evolution, aimed at delivering accessible and life-saving medical solutions at scale. “With a shared passion for impact, progress and a better tomorrow, we are excited to work with E Squared to place our innovations—present and future—in the hands of people around the world,” he said.
Pyi Maung, Head of Investments at E Squared, emphasised the alignment between the firm’s impact-driven investment philosophy and Impulse Biomedical’s socially responsive mission. “Impulse Biomedical’s mission and innovation represent the kind of purpose-driven entrepreneurship South Africa and the world needs,” Maung noted, highlighting the startup’s capacity to deliver measurable social outcomes alongside commercial success.
The funding underscores a growing recognition of South Africa’s potential as a hub for med-tech innovation, particularly in domains where frugal engineering intersects with public health imperatives. As the global demand for scalable and affordable medical technologies continues to grow, Impulse Biomedical’s trajectory represents a promising example of how African innovation can address pressing global healthcare challenges.
